RxDoctor Payments Data

Christopher Wee, MD

Hematology & Oncology · Cleveland, OHNPI 1225457583

Payments from drug & device makers

$515,296in general payments, 2019–2025

Across 66 payments — averaging $7807.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$477K
  • Bayer$15K
  • Johnson & Johnson$11K
  • Pfizer$11K
  • Janssen Scientific Affairs, LLC$818
  • Organon$739
  • plus $720 from 5 others

What the payments were for

  • Consulting fees$23,55363%
  • Speaking & faculty fees$7,95021%
  • Travel & lodging$4,19311%
  • Food & beverage$1,8155%
  • Education$750%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515,296 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$60,362
Medicare patients
238
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide122$1,684,466
XtandiEnzalutamide49$630,356
InlytaAxitinib27$449,281
NubeqaDarolutamide35$433,993
CabometyxCabozantinib S-Malate22$379,135
OrgovyxRelugolix120$323,032
Abiraterone Acetate124$276,817
Prednisone230$789
Bicalutamide25$723
Hydrocortisone11$473
Ondansetron Hcl11$343
Tamsulosin Hcl22$210
Chlorthalidone12$198
Venlafaxine Hcl ErVenlafaxine Hcl36$175
Levothyroxine Sodium15$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$10,924$1,684,466122 claims
PfizerInlyta$10,524$449,28127 claims
BayerNubeqa$14,601$433,99335 claims
Exelixis Inc.Cabometyx$134$379,13522 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$818$276,817124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →